CPL (Contract Pharmaceuticals Limited) is pleased to announce that research presented by Lucy Zhao at the 2025 AAPS PharmSci360 was selected for the prestigious Special Poster Collection. Her study introduces a high-throughput screening platform that revolutionizes how scientists evaluate mucosal drug delivery systems.

The research, titled “High-Throughput In Vitro Permeation Models for Comparative Assessment of Mucoadhesive Formulations,” focuses on overcoming the limitations of traditional oral and injectable delivery. By utilizing MatTek 3D human respiratory epithelial tissues and porcine intestinal membranes, Zhao developed a physiologically relevant model to compare how different polymers – specifically Hydroxypropyl Cellulose (HPC) and Hydroxyethyl Cellulose (HEC) – impact drug release.

Key Findings from the Award-Winning Research:

  • HPC vs. HEC Performance: The study found that while HEC-based formulations offer faster initial release, HPC-based formulations provide a smoother, more controlled, and sustained permeation profile over time.
  • Innovative Testing Models: Zhao successfully utilized In Vitro Permeation Testing (IVPT) and Franz diffusion cells to create a reliable, discriminative tool for predicting how nasal sprays and gels will behave in the human body.
  • Improved Bioavailability: The research highlights how mucoadhesive polymers allow drugs to stay longer at the absorption site, supporting more targeted dosing and faster absorption into the bloodstream.

“Being selected for the Special Poster Collection is a testament to CPL’s commitment to scientific excellence,” said Lucy Zhao. “Our model provides a high-throughput platform that can significantly accelerate the development of effective, non-invasive mucosal therapies.”

Zhao extends her sincere gratitude to Miko Zhong, Chetan Chure and Jigar Patel for their invaluable collaboration and support throughout this project. To learn more about CPL’s specialized research and development services, visit the CPL official website.

About CPL

CPL is a leading Contract Development and Manufacturing Organization (CDMO) specializing in non-sterile liquid and semi-solid dosage forms. From early-stage formulation to commercial manufacturing, CPL provides integrated solutions for the global pharmaceutical industry.